#Minneapolis #Australia #Neuromodulation #Saluda Medical #Evoke System

Saluda Medical's Significant Funding Boost Post-IPO

On December 9, 2025, Saluda Medical, Inc. made headlines by successfully raising approximately $150 million following its initial public offering (IPO) on the Australian Securities Exchange (ASX) under the ticker symbol "SLD". This significant fundraising effort, which garnered a total of around A$230.8 million, consisted of approximately 87.1 million new CHESS Depositary Interests (CDIs) priced at A$2.65 per share.

The funds raised from this IPO will be instrumental in propelling Saluda's ambitious agenda, allowing the company to enhance its sales team, broaden marketing efforts, and further develop its cutting-edge medical devices.

Saluda Medical, known for its innovative approach to treating chronic neurological conditions, leverages a proprietary closed-loop neuromodulation platform. This platform is designed to deliver tailored treatments through real-time adjustments based on patient responses, distinguishing it from traditional methods.

Barry Regan, President and CEO of Saluda Medical, expressed optimism about this new chapter for the company. He stated, "This IPO and capital raise mark an important moment for Saluda. With strong clinical evidence and a scalable commercial model, we are now even better positioned to accelerate our mission globally. This funding enables us to expand our U.S. footprint, invest in innovation, and deliver on our commitment to transform patient care worldwide."

Saluda's Innovative Technology

Developed over a span of 15 years, the Evoke® System is at the forefront of Saluda's product line. This system is lauded as the first spinal cord stimulation (SCS) device capable of reading and responding to the spinal cord's evoked compound action potentials (ECAPs) in real-time. Its unique capabilities are supported by extensive clinical data, with a notable 83% of patients achieving at least a 50% reduction in pain at the 36-month mark.

Existing stakeholders in Saluda include notable investment firms such as Wellington Management, Fidelity Management Research Company, and T. Rowe Price Associates, among others. Their participation underscores the confidence in Saluda's potential for growth and impact in the medical device sector.

The Future of Patient Care

Industry experts, including Jason E. Pope, MD, Founder and CEO of Evolve Restorative Center in Santa Rosa, CA, recognize the significance of Saluda's technology. Dr. Pope stated, "Saluda's technology is a true paradigm shift in the world of neuromodulation. By delivering closed-loop stimulation tailored to each patient's physiology, it sets a new standard of care for personalized pain management."

As Saluda Medical embarks on its journey of growth and innovation post-IPO, it aims to not only expand its market presence but also to enhance patient access to groundbreaking therapies. This shift towards more personalized and effective pain management solutions represents a pivotal moment in the treatment of chronic pain.

For more information about Saluda Medical and their innovative therapies, check out their website at Saluda Medical.

Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd.